Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression.

depression ketamine plasma vascular endothelial growth factor

Journal

Therapeutic advances in psychopharmacology
ISSN: 2045-1253
Titre abrégé: Ther Adv Psychopharmacol
Pays: England
ID NLM: 101555693

Informations de publication

Date de publication:
2021
Historique:
received: 26 10 2020
accepted: 13 04 2021
entrez: 26 5 2021
pubmed: 27 5 2021
medline: 27 5 2021
Statut: epublish

Résumé

Growing evidence suggests that vascular endothelial growth factor (VEGF) may be involved in the neuronal mechanisms underlying both depression aetiology and the response to ketamine treatments. The aim of this study was to examine whether changes in plasma VEGF levels are associated with the antidepressant effects of repeated ketamine infusions in patients with depression. Ninety-six patients with depression were enrolled and received six ketamine infusions during a 12-day period. Depressive symptom severity and plasma VEGF levels were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and an enzyme-linked immunosorbent assay (ELISA) respectively, at baseline, 13 days and 26 days. Despite a significant improvement in MADRS scores after patients received six ketamine infusions ( This study indicated that VEGF may not be a potential predictor of antidepressant response to repeated intravenous administration of ketamine in patients with depression.

Identifiants

pubmed: 34035893
doi: 10.1177/20451253211014320
pii: 10.1177_20451253211014320
pmc: PMC8132091
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20451253211014320

Informations de copyright

© The Author(s), 2021.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declare that there is no conflict of interest.

Références

J Psychopharmacol. 2019 Apr;33(4):494-501
pubmed: 30789302
Psychol Med. 2016 May;46(7):1459-72
pubmed: 26867988
Nat Genet. 2004 Aug;36(8):827-35
pubmed: 15258583
Biol Psychiatry. 2006 Jun 15;59(12):1116-27
pubmed: 16631126
J Clin Psychiatry. 2015 Feb;76(2):155-62
pubmed: 25742202
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1322-5
pubmed: 21570438
Curr Opin Pharmacol. 2008 Feb;8(1):14-9
pubmed: 18061540
Biol Psychiatry. 2015 Feb 1;77(3):e19-e20
pubmed: 25104172
Genes Dev. 2011 Apr 15;25(8):831-44
pubmed: 21498572
Eur J Neurosci. 2005 Mar;21(5):1304-14
pubmed: 15813940
Bioessays. 2004 Sep;26(9):943-54
pubmed: 15351965
Biol Psychiatry. 2019 Jul 15;86(2):143-152
pubmed: 30712809
CNS Drugs. 2009 Aug;23(8):627-47
pubmed: 19594193
Hong Kong Med J. 2018 Apr;24(2):175-181
pubmed: 29632275
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
Arch Gen Psychiatry. 2010 Aug;67(8):793-802
pubmed: 20679587
J Psychopharmacol. 2013 May;27(5):444-50
pubmed: 23428794
J Psychiatr Res. 2018 Nov;106:61-68
pubmed: 30278319
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Brain Behav Immun. 2018 Nov;74:205-212
pubmed: 30213652
Neuropsychopharmacology. 2009 Oct;34(11):2459-68
pubmed: 19553916
J Psychiatr Res. 2004 Nov-Dec;38(6):577-82
pubmed: 15458853
J Affect Disord. 2019 Jan 15;243:516-524
pubmed: 30286416
J Neurosci. 2005 Sep 28;25(39):8889-97
pubmed: 16192378
Brain Res Mol Brain Res. 2005 May 20;136(1-2):29-37
pubmed: 15893584
J Affect Disord. 2014 Feb;155:123-9
pubmed: 24268616
J Affect Disord. 2019 May 15;251:205-212
pubmed: 30927581
J Neurosci. 2004 Mar 17;24(11):2667-77
pubmed: 15028759
J Clin Psychiatry. 2017 Jun;78(6):e674-e677
pubmed: 28682536
Neuropharmacology. 2012 Sep;63(4):642-52
pubmed: 22580375
Neuropeptides. 2012 Feb;46(1):1-10
pubmed: 21719103
Transl Psychiatry. 2012 Nov 20;2:e196
pubmed: 23168996
J Consult Clin Psychol. 1979 Apr;47(2):343-52
pubmed: 469082
Psychol Med. 2015 Dec;45(16):3571-80
pubmed: 26266877
J Affect Disord. 2020 Mar 15;265:63-70
pubmed: 31957693
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Am J Psychiatry. 2018 Feb 01;175(2):150-158
pubmed: 28969441
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52
pubmed: 17360578
Biochim Biophys Acta. 2016 Jul;1862(7):1247-54
pubmed: 27063455

Auteurs

Wei Zheng (W)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Yan-Ling Zhou (YL)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Cheng-Yu Wang (CY)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Xiao-Feng Lan (XF)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Bin Zhang (B)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Su-Miao Zhou (SM)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Su Yan (S)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Ming-Zhe Yang (MZ)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Sha Nie (S)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Yu-Ping Ning (YP)

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Classifications MeSH